SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Immuneering Presents Design and Methodology of Phase 3 Trial

Immuneering presented the design and methodology of its ongoing Phase 3 MAPKeEPR 301 trial at the 2026 ESMO Congress.

IMRX

Related stories